Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Sarcopenia Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Sarcopenia Overview | 8 | 1 |
| Pipeline Products for Sarcopenia Comparative Analysis | 9 | 1 |
| Sarcopenia Therapeutics under Development by Companies | 10 | 1 |
| Sarcopenia Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Sarcopenia Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Sarcopenia Products under Development by Companies | 14 | 1 |
| Sarcopenia Products under Investigation by Universities/Institutes | 15 | 1 |
| Sarcopenia Companies Involved in Therapeutics Development | 16 | 9 |
| Atara Biotherapeutics, Inc. | 16 | 1 |
| Biophytis SAS | 17 | 1 |
| GlaxoSmithKline Plc | 18 | 1 |
| MYOS RENS Technology Inc. | 19 | 1 |
| Neurotune AG | 20 | 1 |
| Novartis AG | 21 | 1 |
| PsiOxus Therapeutics Limited | 22 | 1 |
| Regeneron Pharmaceuticals, Inc. | 23 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 24 | 1 |
| Sarcopenia Therapeutics Assessment | 25 | 9 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 19 |
| ARM-210 Drug Profile | 34 | 2 |
| ATA-842 Drug Profile | 36 | 1 |
| bimagrumab Drug Profile | 37 | 2 |
| BIO-101 Drug Profile | 39 | 1 |
| Cell Therapy for Sarcopenia Drug Profile | 40 | 1 |
| DA-4210 Drug Profile | 41 | 1 |
| espindolol Drug Profile | 42 | 2 |
| Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis Drug Profile | 44 | 1 |
| NEP-28 Drug Profile | 45 | 1 |
| NT-1654 Drug Profile | 46 | 1 |
| Proteins for Musculoskeletal Disorders Drug Profile | 47 | 1 |
| Recombinant Protein for Sarcopenia Drug Profile | 48 | 1 |
| S-107 Drug Profile | 49 | 1 |
| Small Molecules to Inhibit Furin for Sarcopenia and Cachexia Drug Profile | 50 | 1 |
| Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia Drug Profile | 51 | 1 |
| trevogrumab Drug Profile | 52 | 1 |
| Sarcopenia Dormant Projects | 53 | 1 |
| Sarcopenia Discontinued Products | 54 | 1 |
| Sarcopenia Product Development Milestones | 55 | 5 |
| Featured News &Press Releases | 55 | 1 |
| Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th | 55 | 1 |
| Nov 17, 2015: Biophytis establishes Boston subsidiary to accelerate clinical development of Sarcob | 55 | 1 |
| Sep 21, 2015: BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity | 55 | 1 |
| Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference | 56 | 1 |
| Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia | 57 | 1 |
| Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics | 58 | 2 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |